The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors
Abstract
A comparison has been made of [(123)I]meta-iodobenzylguanidine ([(123)I]MIBG) and [(111)In]pentetreotide scintigraphy in 54 patients with a variety of neuroendocrine tumors of whom 46 patients had metastatic disease. [(111)In]Pentetreotide scintigraphy was more sensitive in detecting metastatic lesions, as demonstrated on computed tomography and/or magnetic resonance scanning, than [(123)I]MIBG: 67% vs. 50% for carcinoid tumors (n = 24), 91% vs. 9% for pancreatic islet cell tumors (n = 12), 100% vs. 60% for medullary thyroid carcinomas (n = 5), and 75% vs. 100% for pheochromocytomas/paragangliomas (n = 4). In only 2 patients were lesions seen with [(123)I]MIBG scanning that were not apparent with [(111)In]pentetreotide. With the exception of pancreatic islet cell tumors, both radionuclides exhibited a similar sensitivity in detecting hepatic metastases, whereas in three patients the two radionuclides exerted a complementary role as different deposits exhibited uptake to only 1 or the other radionuclide. Hepatic metastases were the most important clinical predictor of a positive scan for both radionuclides. Neither elevated 5-hydroxyindoleacetic acid levels nor any other hormonal marker was predictive of a positive scan. In 8 patients with clinical and/or hormonal evidence of a neuroendocrine tumor but negative conventional radiology, [(111)In]pentetreotide scintigraphy was more sensitive than [(123)I]MIBG (37.5% vs. 12.5%) in detecting lesions. In conclusion, scintigraphy with [(111)In]pentetreotide detects more metastatic lesions than [(123)I]MIBG in patients with carcinoid and pancreatic islet cell tumors and medullary thyroid carcinomas; [(123)I]MIBG scintigraphy may be more sensitive for sympathoadrenomedullary tumors. The radionuclides may exert a complementary role in the detection and treatment of neuroendocrine tumors in occasional patients, as areas of different pattern of uptake were identified within the same patient. These data have implications not only for staging such tumors, but also for identifying patients who might benefit from treatment using either [(131)I]MIBG or radioactive somatostatin analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Somatostatin analogue scintigraphy in carcinoid tumours
Kwekkeboom, D., Krenning, E., Bakker, W., Oei, H. Y., Kooij, P. M., & Lamberts, S. J. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00169802 · Cited by 185
Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours
Hoefnagel, C. A. (1994) · European Journal of Nuclear Medicine · doi:10.1007/bf00173045 · Cited by 184
Tenenbaum, F., Lumbroso, J., Schlumberger, M. J., Mure, A., Plouin, P., Caillou, B., & Parmentier, C. (1995) · PubMed · Cited by 139
Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment
Öberg, K. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_2.s3 · Cited by 132
Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues
Wiseman, G. A., & Kvols, L. K. (1995) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(95)80016-6 · Cited by 94
The Neuroendocrine Concept Today
Langley, K. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17251.x · Cited by 89
Kopf, D., Bockisch, A., Steinert, H. C., Hahn, K. M., Beyer, J., Neumann, H. P. H., Hensen, J., & Lehnert, H. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1738.x · Cited by 69
(1995) · Medical Entomology and Zoology · Cited by 57
Drake, W. M., Miraki‐Moud, F., Siddiqi, A., Yateman, M., Barnes, N., Camacho-Hübner, C., & Monson, J. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390532 · Cited by 30
Cited by
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Self-citationEndocrine tumours of the pancreas
Öberg, K., & Eriksson, B. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.06.002 · Cited by 543
Metadata
- Authors
- Kaltsas, G.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-02-01
- Volume
- 86
- Issue
- 2
- Pages
- 895-902
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2148394335
- Cited by
- 275
- References
- 13
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1210/jc.86.2.895
- The paper
- Kaltsas, G. (2001). Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.86.2.895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.